Therapeutics >

CCR5-Specific Human Monoclonal Antibodies for HIV

Background:
Antibodies are available for collaborative research toward commercialization and/or exclusive and non-exclusive licensing. In vitro data is available at this time.

Technology:
The HIV co-receptor CCR5 has been demonstrated to play an important role in virus entry. This invention describes anti-CCR5 monoclonal antibodies, their fusion protein, conjugates, derivatives, or fragments, DNA sequences encoding such antibodies, host cells containing such DNA sequences, as well as the methods to produce them recombinantly and their pharmacological composition. The subject antibodies exhibited neutralization activity against HIV-1 infection by binding to cell associated CCR5 in vitro. Moreover, these antibodies have potentially lower immunogenicity and toxicity because they are fully human antibodies. These anti-CCR5 antibodies have potential as therapeutics and/or prophylactics in combination with other HIV-1 neutralizing antibodies and anti-retroviral drugs.

Related Publications:

C Pastori et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood. 2006 Jun 15;107(12):4825-4833.
DS Dimitrov. Fusin - a place for HIV-1 and T4 cells to meet. Nature Med. 1996 Jun;2(6):640-641.

Contact Information:
John D. Hewes, Ph.D., NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov

Reference: #430 JH

Updated 10/25/2007

MOST RECENT CRADA OPPORTUNITIES

Methods To Treat Fatty Liver Disease

Transgenic Mouse Model For Development Of Cancer Therapeutics

Therapeutics Based On The Induced Internalization Of Surface Receptors

E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008